nodes	percent_of_prediction	percent_of_DWPC	metapath
Carbinoxamine—CYP2E1—Mitoxantrone—lymphatic system cancer	0.192	0.248	CbGbCtD
Carbinoxamine—CYP2C19—Teniposide—lymphatic system cancer	0.172	0.223	CbGbCtD
Carbinoxamine—CYP2C9—Teniposide—lymphatic system cancer	0.143	0.185	CbGbCtD
Carbinoxamine—CYP3A4—Cytarabine—lymphatic system cancer	0.0842	0.109	CbGbCtD
Carbinoxamine—CYP3A4—Teniposide—lymphatic system cancer	0.083	0.108	CbGbCtD
Carbinoxamine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.058	0.0753	CbGbCtD
Carbinoxamine—CYP3A4—Vincristine—lymphatic system cancer	0.0399	0.0518	CbGbCtD
Carbinoxamine—Haemolytic anaemia—Mechlorethamine—lymphatic system cancer	0.00675	0.0295	CcSEcCtD
Carbinoxamine—Haemolytic anaemia—Teniposide—lymphatic system cancer	0.00497	0.0217	CcSEcCtD
Carbinoxamine—Neuritis—Vincristine—lymphatic system cancer	0.00445	0.0194	CcSEcCtD
Carbinoxamine—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.00438	0.0191	CcSEcCtD
Carbinoxamine—Tinnitus—Mechlorethamine—lymphatic system cancer	0.00393	0.0172	CcSEcCtD
Carbinoxamine—Wheezing—Bleomycin—lymphatic system cancer	0.00387	0.0169	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Teniposide—lymphatic system cancer	0.00339	0.0148	CcSEcCtD
Carbinoxamine—Sweating increased—Fludarabine—lymphatic system cancer	0.00332	0.0145	CcSEcCtD
Carbinoxamine—Vertigo—Mechlorethamine—lymphatic system cancer	0.0033	0.0144	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Fludarabine—lymphatic system cancer	0.00298	0.013	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00293	0.0128	CcSEcCtD
Carbinoxamine—Anorexia—Mechlorethamine—lymphatic system cancer	0.00285	0.0125	CcSEcCtD
Carbinoxamine—Chills—Teniposide—lymphatic system cancer	0.00279	0.0122	CcSEcCtD
Carbinoxamine—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.0026	0.0114	CcSEcCtD
Carbinoxamine—Diplopia—Carmustine—lymphatic system cancer	0.00253	0.011	CcSEcCtD
Carbinoxamine—Agitation—Teniposide—lymphatic system cancer	0.00249	0.0109	CcSEcCtD
Carbinoxamine—Chills—Fludarabine—lymphatic system cancer	0.00245	0.0107	CcSEcCtD
Carbinoxamine—Urinary retention—Vincristine—lymphatic system cancer	0.00229	0.01	CcSEcCtD
Carbinoxamine—Confusional state—Teniposide—lymphatic system cancer	0.00223	0.00972	CcSEcCtD
Carbinoxamine—Agitation—Fludarabine—lymphatic system cancer	0.00218	0.00954	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00216	0.00944	CcSEcCtD
Carbinoxamine—Tachycardia—Teniposide—lymphatic system cancer	0.00215	0.00941	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00213	0.00932	CcSEcCtD
Carbinoxamine—Anorexia—Teniposide—lymphatic system cancer	0.0021	0.00919	CcSEcCtD
Carbinoxamine—Hypotension—Teniposide—lymphatic system cancer	0.00206	0.00901	CcSEcCtD
Carbinoxamine—Convulsion—Fludarabine—lymphatic system cancer	0.00206	0.009	CcSEcCtD
Carbinoxamine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00205	0.00895	CcSEcCtD
Carbinoxamine—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00198	0.00864	CcSEcCtD
Carbinoxamine—Confusional state—Fludarabine—lymphatic system cancer	0.00196	0.00854	CcSEcCtD
Carbinoxamine—Decreased appetite—Teniposide—lymphatic system cancer	0.00192	0.00838	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00191	0.00833	CcSEcCtD
Carbinoxamine—Vomiting—Mechlorethamine—lymphatic system cancer	0.0019	0.00831	CcSEcCtD
Carbinoxamine—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.0019	0.00831	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.0019	0.0083	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00188	0.00819	CcSEcCtD
Carbinoxamine—Anorexia—Fludarabine—lymphatic system cancer	0.00185	0.00808	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00182	0.00796	CcSEcCtD
Carbinoxamine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00182	0.00794	CcSEcCtD
Carbinoxamine—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00181	0.0079	CcSEcCtD
Carbinoxamine—Chills—Bleomycin—lymphatic system cancer	0.0018	0.00785	CcSEcCtD
Carbinoxamine—Nausea—Mechlorethamine—lymphatic system cancer	0.00178	0.00777	CcSEcCtD
Carbinoxamine—Urticaria—Teniposide—lymphatic system cancer	0.00175	0.00766	CcSEcCtD
Carbinoxamine—Paraesthesia—Fludarabine—lymphatic system cancer	0.00174	0.00761	CcSEcCtD
Carbinoxamine—Dyspepsia—Fludarabine—lymphatic system cancer	0.00171	0.00746	CcSEcCtD
Carbinoxamine—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00169	0.00738	CcSEcCtD
Carbinoxamine—Decreased appetite—Fludarabine—lymphatic system cancer	0.00169	0.00737	CcSEcCtD
Carbinoxamine—Fatigue—Fludarabine—lymphatic system cancer	0.00167	0.00731	CcSEcCtD
Carbinoxamine—Constipation—Fludarabine—lymphatic system cancer	0.00166	0.00725	CcSEcCtD
Carbinoxamine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.0016	0.00698	CcSEcCtD
Carbinoxamine—Asthenia—Teniposide—lymphatic system cancer	0.00158	0.00692	CcSEcCtD
Carbinoxamine—Diarrhoea—Teniposide—lymphatic system cancer	0.00151	0.0066	CcSEcCtD
Carbinoxamine—Chills—Mitoxantrone—lymphatic system cancer	0.00146	0.00637	CcSEcCtD
Carbinoxamine—Confusional state—Bleomycin—lymphatic system cancer	0.00143	0.00626	CcSEcCtD
Carbinoxamine—Vision blurred—Carmustine—lymphatic system cancer	0.00143	0.00626	CcSEcCtD
Carbinoxamine—Tremor—Carmustine—lymphatic system cancer	0.00143	0.00623	CcSEcCtD
Carbinoxamine—Vomiting—Teniposide—lymphatic system cancer	0.0014	0.00613	CcSEcCtD
Carbinoxamine—Agitation—Carmustine—lymphatic system cancer	0.0014	0.00611	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00139	0.00608	CcSEcCtD
Carbinoxamine—Asthenia—Fludarabine—lymphatic system cancer	0.00139	0.00608	CcSEcCtD
Carbinoxamine—Headache—Teniposide—lymphatic system cancer	0.00138	0.00604	CcSEcCtD
Carbinoxamine—Anorexia—Bleomycin—lymphatic system cancer	0.00136	0.00592	CcSEcCtD
Carbinoxamine—Agitation—Vincristine—lymphatic system cancer	0.00133	0.00583	CcSEcCtD
Carbinoxamine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00133	0.00582	CcSEcCtD
Carbinoxamine—Photosensitivity—Methotrexate—lymphatic system cancer	0.00133	0.00582	CcSEcCtD
Carbinoxamine—Hypotension—Bleomycin—lymphatic system cancer	0.00133	0.00581	CcSEcCtD
Carbinoxamine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00133	0.0058	CcSEcCtD
Carbinoxamine—Convulsion—Carmustine—lymphatic system cancer	0.00132	0.00576	CcSEcCtD
Carbinoxamine—Nausea—Teniposide—lymphatic system cancer	0.00131	0.00573	CcSEcCtD
Carbinoxamine—Vertigo—Vincristine—lymphatic system cancer	0.0013	0.0057	CcSEcCtD
Carbinoxamine—Paraesthesia—Bleomycin—lymphatic system cancer	0.00128	0.00558	CcSEcCtD
Carbinoxamine—Convulsion—Vincristine—lymphatic system cancer	0.00126	0.0055	CcSEcCtD
Carbinoxamine—Confusional state—Carmustine—lymphatic system cancer	0.00125	0.00547	CcSEcCtD
Carbinoxamine—Decreased appetite—Bleomycin—lymphatic system cancer	0.00124	0.0054	CcSEcCtD
Carbinoxamine—Vomiting—Fludarabine—lymphatic system cancer	0.00123	0.00539	CcSEcCtD
Carbinoxamine—Convulsion—Mitoxantrone—lymphatic system cancer	0.00123	0.00535	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00122	0.00531	CcSEcCtD
Carbinoxamine—Headache—Fludarabine—lymphatic system cancer	0.00122	0.00531	CcSEcCtD
Carbinoxamine—Tachycardia—Carmustine—lymphatic system cancer	0.00121	0.00529	CcSEcCtD
Carbinoxamine—Anorexia—Carmustine—lymphatic system cancer	0.00118	0.00517	CcSEcCtD
Carbinoxamine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00117	0.00512	CcSEcCtD
Carbinoxamine—Confusional state—Mitoxantrone—lymphatic system cancer	0.00116	0.00508	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00116	0.00507	CcSEcCtD
Carbinoxamine—Hypotension—Carmustine—lymphatic system cancer	0.00116	0.00507	CcSEcCtD
Carbinoxamine—Nausea—Fludarabine—lymphatic system cancer	0.00115	0.00503	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00115	0.005	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00113	0.00494	CcSEcCtD
Carbinoxamine—Urticaria—Bleomycin—lymphatic system cancer	0.00113	0.00494	CcSEcCtD
Carbinoxamine—Anorexia—Vincristine—lymphatic system cancer	0.00113	0.00493	CcSEcCtD
Carbinoxamine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00113	0.00492	CcSEcCtD
Carbinoxamine—Insomnia—Carmustine—lymphatic system cancer	0.00112	0.0049	CcSEcCtD
Carbinoxamine—Irritability—Methotrexate—lymphatic system cancer	0.00112	0.00488	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00112	0.00487	CcSEcCtD
Carbinoxamine—Paraesthesia—Carmustine—lymphatic system cancer	0.00111	0.00487	CcSEcCtD
Carbinoxamine—Hypotension—Vincristine—lymphatic system cancer	0.00111	0.00484	CcSEcCtD
Carbinoxamine—Somnolence—Carmustine—lymphatic system cancer	0.0011	0.00482	CcSEcCtD
Carbinoxamine—Anorexia—Mitoxantrone—lymphatic system cancer	0.0011	0.00481	CcSEcCtD
Carbinoxamine—Decreased appetite—Carmustine—lymphatic system cancer	0.00108	0.00471	CcSEcCtD
Carbinoxamine—Hypotension—Mitoxantrone—lymphatic system cancer	0.00108	0.00471	CcSEcCtD
Carbinoxamine—Insomnia—Vincristine—lymphatic system cancer	0.00107	0.00468	CcSEcCtD
Carbinoxamine—Paraesthesia—Vincristine—lymphatic system cancer	0.00106	0.00465	CcSEcCtD
Carbinoxamine—Constipation—Carmustine—lymphatic system cancer	0.00106	0.00464	CcSEcCtD
Carbinoxamine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00104	0.00453	CcSEcCtD
Carbinoxamine—Decreased appetite—Vincristine—lymphatic system cancer	0.00103	0.0045	CcSEcCtD
Carbinoxamine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00103	0.00448	CcSEcCtD
Carbinoxamine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00102	0.00447	CcSEcCtD
Carbinoxamine—Fatigue—Vincristine—lymphatic system cancer	0.00102	0.00446	CcSEcCtD
Carbinoxamine—Asthenia—Bleomycin—lymphatic system cancer	0.00102	0.00446	CcSEcCtD
Carbinoxamine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00102	0.00444	CcSEcCtD
Carbinoxamine—Constipation—Vincristine—lymphatic system cancer	0.00101	0.00443	CcSEcCtD
Carbinoxamine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.001	0.00438	CcSEcCtD
Carbinoxamine—Fatigue—Mitoxantrone—lymphatic system cancer	0.000995	0.00435	CcSEcCtD
Carbinoxamine—Constipation—Mitoxantrone—lymphatic system cancer	0.000987	0.00431	CcSEcCtD
Carbinoxamine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000951	0.00415	CcSEcCtD
Carbinoxamine—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000923	0.00403	CcSEcCtD
Carbinoxamine—Urticaria—Mitoxantrone—lymphatic system cancer	0.000917	0.00401	CcSEcCtD
Carbinoxamine—Vomiting—Bleomycin—lymphatic system cancer	0.000904	0.00395	CcSEcCtD
Carbinoxamine—Drowsiness—Methotrexate—lymphatic system cancer	0.000902	0.00394	CcSEcCtD
Carbinoxamine—Asthenia—Carmustine—lymphatic system cancer	0.000891	0.00389	CcSEcCtD
Carbinoxamine—Asthenia—Vincristine—lymphatic system cancer	0.00085	0.00371	CcSEcCtD
Carbinoxamine—Diarrhoea—Carmustine—lymphatic system cancer	0.000849	0.00371	CcSEcCtD
Carbinoxamine—Nausea—Bleomycin—lymphatic system cancer	0.000845	0.00369	CcSEcCtD
Carbinoxamine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000841	0.00368	CcSEcCtD
Carbinoxamine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000828	0.00362	CcSEcCtD
Carbinoxamine—Dizziness—Carmustine—lymphatic system cancer	0.000821	0.00359	CcSEcCtD
Carbinoxamine—Diarrhoea—Vincristine—lymphatic system cancer	0.000811	0.00354	CcSEcCtD
Carbinoxamine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00079	0.00345	CcSEcCtD
Carbinoxamine—Vomiting—Carmustine—lymphatic system cancer	0.000789	0.00345	CcSEcCtD
Carbinoxamine—Dizziness—Vincristine—lymphatic system cancer	0.000784	0.00342	CcSEcCtD
Carbinoxamine—Headache—Carmustine—lymphatic system cancer	0.000778	0.0034	CcSEcCtD
Carbinoxamine—Tinnitus—Methotrexate—lymphatic system cancer	0.000755	0.0033	CcSEcCtD
Carbinoxamine—Vomiting—Vincristine—lymphatic system cancer	0.000753	0.00329	CcSEcCtD
Carbinoxamine—Headache—Vincristine—lymphatic system cancer	0.000742	0.00324	CcSEcCtD
Carbinoxamine—Nausea—Carmustine—lymphatic system cancer	0.000737	0.00322	CcSEcCtD
Carbinoxamine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000734	0.00321	CcSEcCtD
Carbinoxamine—Chills—Methotrexate—lymphatic system cancer	0.000726	0.00317	CcSEcCtD
Carbinoxamine—Headache—Mitoxantrone—lymphatic system cancer	0.000723	0.00316	CcSEcCtD
Carbinoxamine—Nausea—Vincristine—lymphatic system cancer	0.000704	0.00307	CcSEcCtD
Carbinoxamine—Nausea—Mitoxantrone—lymphatic system cancer	0.000685	0.00299	CcSEcCtD
Carbinoxamine—Vision blurred—Methotrexate—lymphatic system cancer	0.000664	0.0029	CcSEcCtD
Carbinoxamine—Vertigo—Methotrexate—lymphatic system cancer	0.000633	0.00277	CcSEcCtD
Carbinoxamine—Convulsion—Methotrexate—lymphatic system cancer	0.00061	0.00267	CcSEcCtD
Carbinoxamine—Confusional state—Methotrexate—lymphatic system cancer	0.00058	0.00253	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000563	0.00246	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000556	0.00243	CcSEcCtD
Carbinoxamine—Anorexia—Methotrexate—lymphatic system cancer	0.000548	0.00239	CcSEcCtD
Carbinoxamine—Hypotension—Methotrexate—lymphatic system cancer	0.000537	0.00235	CcSEcCtD
Carbinoxamine—Insomnia—Methotrexate—lymphatic system cancer	0.00052	0.00227	CcSEcCtD
Carbinoxamine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000516	0.00226	CcSEcCtD
Carbinoxamine—Somnolence—Methotrexate—lymphatic system cancer	0.000511	0.00223	CcSEcCtD
Carbinoxamine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000506	0.00221	CcSEcCtD
Carbinoxamine—Decreased appetite—Methotrexate—lymphatic system cancer	0.0005	0.00218	CcSEcCtD
Carbinoxamine—Fatigue—Methotrexate—lymphatic system cancer	0.000496	0.00217	CcSEcCtD
Carbinoxamine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000474	0.00207	CcSEcCtD
Carbinoxamine—Urticaria—Methotrexate—lymphatic system cancer	0.000457	0.002	CcSEcCtD
Carbinoxamine—Asthenia—Methotrexate—lymphatic system cancer	0.000413	0.0018	CcSEcCtD
Carbinoxamine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000393	0.00172	CcSEcCtD
Carbinoxamine—Dizziness—Methotrexate—lymphatic system cancer	0.00038	0.00166	CcSEcCtD
Carbinoxamine—Vomiting—Methotrexate—lymphatic system cancer	0.000366	0.0016	CcSEcCtD
Carbinoxamine—Headache—Methotrexate—lymphatic system cancer	0.00036	0.00157	CcSEcCtD
Carbinoxamine—Nausea—Methotrexate—lymphatic system cancer	0.000342	0.00149	CcSEcCtD
